Actively Recruiting
Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation
Led by Shahid Beheshti University of Medical Sciences · Updated on 2025-06-24
50
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf®/Astagraf XL®, Astellas company).
CONDITIONS
Official Title
Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All kidney transplant recipients
You will not qualify if you...
- Kidney-pancreas transplant recipients
- Body mass index (BMI) greater than 30
- Calculated panel reactive antibody (cPRA) greater than 0%
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nooshin Dalili
Tehran, Iran, 1666663421
Actively Recruiting
Research Team
P
PI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here